Board Of Directors

William Jarosz, JD - Chairman of the Board of Directors

Richard Barker, DPhil, BA - Director

Noel Hall, BSc - Director

Andrew J. Rae, MBA - President, CEO and Director

Douglas G. Janzen 

William Jarosz, JD - Chairman of the Board of Directors

Partner, Cartesian Capital Group, LLC

William Jarosz is currently a Partner at Cartesian Capital Group, LLC, a global investment management firm. From 1997 until 2005, Mr. Jarosz served as Managing Director and General Counsel of AIG Capital Partners, a subsidiary of American International Group, Inc., and as Managing Director of the AIG-Brunswick Millennium Fund. While at AIG Capital Partners, Mr. Jarosz oversaw global private equity transactions for the firm's various private equity funds. Prior to joining AIG in 1997, Mr.Jarosz practiced law at Debevoise & Plimpton, specializing in international private equity investment and Russian corporate and securities laws. Mr. Jarosz also served as a consultant to the World Bank on the regulation of Foreign Direct Investment in emerging markets. Mr. Jarosz is a graduate of the University of Montana, and received an MA in Law and Diplomacy from the Fletcher School at Tufts University and a JD from Harvard Law School.

top

Richard Barker, DPhil, BA - Director

Former Director General of the Association of the British Pharmaceutical Industry (ABPI)

Dr Richard W. Barker was Director General of the Association of the British Pharmaceutical Industry from August 2004 to May 2011. Prior to joining APBI, Dr. Barker was the Founder and President of New Medicine Partners, CEO of iKnowMed, Chief Executive of Chiron Diagnostics, General Manager of IBM's Worldwide Healthcare Solutions division, and leader of McKinsey's European healthcare practice. He is currently a board member of Celgene Corporation, the European Federation of Pharmaceutical Manufacturers and Associations (EFPIA) and council member of the international equivalent body (IFPMA). He also serves on the board of Adlyfe, a company specializing in protein misfolding diseases. Dr. Barker's academic background includes research in biological magnetic resonance at Oxford, Leeds and Munich. He holds a D.Phil in biophysics and a B.A. in chemistry, both from Oxford University.

top

Noel Hall, BSc - Director

Former Co-founder, President & Director of Aspreva Pharmaceuticals

Noel Hall is currently a consultant to the life sciences industry and has approximately 25 years experience in the biotechnology industry, including as president of Aspreva Pharmaceuticals Corporation, which was acquired by the Galenica Group in January 2008. Prior to co-founding Aspreva in December 2001, Mr. Hall co-founded the life sciences practice of consulting firm Hill and Knowlton in 1995 and served as head of global strategic planning for the firm's worldwide pharmaceutical consulting practice. From 1992 to 1995, Mr. Hall was the director of corporate affairs for the United Kingdom and Northern Europe for The Wellcome Foundation Ltd., which is now part of GlaxoSmithKline PLC. From 1985 to 1990, Mr. Hall worked in market development with Abbott Laboratories Ltd. and from 1983 to 1985 Mr. Hall was a regional sales manager with Leo Laboratories Ltd. Mr. Hall holds a BSc in Medical Laboratory Science from London University.

top

Andrew J. Rae, MBA - President, CEO and Director

Mr. Rae is President and CEO of iCo Therapeutics, Inc., an ocular development company he co-founded in 2005. Andrew has spent a decade in the biotechnology industry, formerly as CFO with Ability Biomedical Corporation (Irvine CA, Vancouver BC), acquired by Medarex, Inc. in 2004. Mr. Rae has also served as Vice President, Finance & Corporate Affairs at Active Pass Pharmaceuticals (Vancouver BC). In his various roles, Mr. Rae has raised approximately $50M in venture, strategic and capital markets financings, engaged in a successful cross-border M&A transaction, and played a significant role in shaping multiple business development deals (Cambridge Antibody, Isis Pharmaceuticals, Medarex). Prior to his operational experiences, Mr. Rae served as Biotechnology Equities Analyst, Goepel Shields & Partners (now Raymond James Canada), covering Canadian biotechnology stocks including Angiotech Pharmaceuticals, QLT Inc. and ID Biomedical.

Mr. Rae currently sits on the Dean's External Advisory Board for the Faculty of Business Administration at Simon Fraser University, the Board of Directors of Carrus Capital Corporation, a Vancouver-based merchant bank, the BCIT/University of British Columbia BSc in Biotechnology, Honours Program Advisory Committee, and the Board of Directors of Covenant House Vancouver, a charity operating shelters and counsel to homeless youth in Vancouver, BC. In 2009 Andrew was Pacific Finalist, Ernst & Young Entrepreneur of the Year (Canada). Mr. Rae's degrees include a B.Sc. from the University of Western Ontario and an MBA from Simon Fraser University.

top

 Douglas G. Janzen

Mr. Janzen currently serves as President, Chief Executive Officer and a Director of Cardiome Pharma Corp. (NASDAQ:CRME, TSX:COM).   Mr. Janzen joined Cardiome in 2003 as Chief Financial Officer, and served as President and Chief Business Officer from March 2006 to August 2009, at which time he assumed the role of CEO.  He has been instrumental in developing and implementing Cardiome’s operational strategy, in the advancement of Cardiome’s corporate development and the strengthening of its financial position, including obtaining a NASDAQ listing.  Mr. Janzen also currently serves as a director of NEOVASC INC. and as a director of various industry trade associations, including Chairman of the board of directors of Life Sciences British Columbia.  Prior to joining Cardiome, Mr. Janzen served as Managing Director, Health Sciences and Partner at Sprott Securities, Inc., a Toronto-based investment bank and was instrumental in raising over $1Billion for Canadian healthcare companies during his career. 

top